Loading...
•
Jun 30, 2022
Gossamer Bio Q2 2022 Earnings Report
Announced second quarter 2022 financial results and provided business update.
Key Takeaways
Gossamer Bio reported a net loss of $56.5 million for the second quarter of 2022, with cash, cash equivalents, and marketable securities totaling $222.2 million as of June 30, 2022.
Seralutinib Phase 2 TORREY Study on track for topline readout in second half of November or first half of December.
CNS-penetrant GB5121 doses first patient in Phase 1b/2 STAR CNS Study in PCNSL and other rare CNS malignancies.
Cash, cash equivalents & marketable securities totaled $342 million as of June 30, 2022, pro forma for $120 million private placement financing in July 2022.
Company has commenced investment in operational activities to enable the commencement of a registrational PAH Phase 3 clinical program in the third quarter of 2023.
Gossamer Bio
Gossamer Bio
Forward Guidance
Gossamer Bio anticipates the combination of current cash, cash equivalents and marketable securities, and access to its debt facility will be sufficient to fund its operating and capital expenditures into the second quarter of 2024.